aTyr Pharma (ATYR) News Today

aTyr Pharma, Inc. (NASDAQ:ATYR) shares rose modestly today despite heavy trading, as investors grapple with the fallout from a failed Phase III trial, multiple analyst downgrades and the launch of securities‐fraud investigations.

• Neutral Sentiment: Leerink Partners reaffirmed its “market perform” rating on ATYR with a $1.00 price target.aTyr Pharma's (ATYR) Market Perform Rating Reiterated at Leerink Partners
• Neutral Sentiment: Wells Fargo & Company reiterated an “equal weight” rating on ATYR shares.ATYR Rating Reaffirmed at Wells Fargo
• Neutral Sentiment: aTyr Pharma hosted a special call and released a slideshow detailing top-line Phase III EFZO-FIT results in pulmonary sarcoidosis.aTyr Pharma, Inc. (ATYR) Special Call - Slideshow
• Neutral Sentiment: Trading in ATYR was briefly halted due to pending news, resuming once the trial data were announced.
• Negative Sentiment: The Phase III EFZO-FIT study failed to meet its primary endpoint at week 48, though 52.6% of patients on efzofitimod achieved complete steroid withdrawal versus 40.2% on placebo (p=0.0919).aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis
• Negative Sentiment: aTyr’s experimental lung-disease drug failed to meet the main goal in late-stage testing, sending shares sharply lower.aTyr Pharma's lung disease drug misses main goal in late-stage trial
• Negative Sentiment: Shares plummeted more than 80%, hitting record lows after the study failure.ATyr Pharma Shares Plummet More Than 80% After Study Failure
• Negative Sentiment: HC Wainwright downgraded ATYR from “buy” to “neutral.”aTyr Pharma (NASDAQ:ATYR) Lowered to Neutral Rating by HC Wainwright
• Negative Sentiment: Cantor Fitzgerald cut its rating from “overweight” to “neutral.”aTyr Pharma (NASDAQ:ATYR) Rating Lowered to Neutral at Cantor Fitzgerald
• Negative Sentiment: Zacks downgraded ATYR from “strong-buy” to “hold.”ATYR Downgraded to Hold at Zacks
• Negative Sentiment: Investors were urged to contact the DJS Law Group over potential securities-fraud violations related to the trial disclosures.aTyr Pharma, Inc. Investigated for Securities Fraud Violations – ATYR
• Negative Sentiment: Block & Leviton launched an investigation after ATYR shares plunged roughly 80%.BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton